CN105796564B - A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp - Google Patents
A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp Download PDFInfo
- Publication number
- CN105796564B CN105796564B CN201610225691.4A CN201610225691A CN105796564B CN 105796564 B CN105796564 B CN 105796564B CN 201610225691 A CN201610225691 A CN 201610225691A CN 105796564 B CN105796564 B CN 105796564B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- tooth body
- dental pulp
- preventing
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
Abstract
The present invention relates to a kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp, described pharmaceutical composition includes the compound and pharmaceutically acceptable carrier of effective dose, and the compound has having structure：
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of drug regimen for preventing and treating tooth body infections of dental pulp
Thing.
Background technology
The disease of hard tooth tissue is referred to as tooth body disease, and the tooth body disease of broad sense also includes dental pulp disease.Dental caries are one kind by oral cavity
Hard tooth tissue caused by middle many factors compound action carries out lesions, shows as the demineralization of inanimate matter and point of organic matter
Solution, has a color and luster to change to the evolution process to form substantive lesions with the development of the course of disease.The World Health Organization is by it
The big keypoint control disease of the mankind three is listed as with cancerous swelling and angiocardiopathy.Its often caused by caused by various pathogens, because
This research has great importance for the suppression of pathogenic bacteria for preventing and treating tooth body infections of dental pulp.Bacteroides fragilis is found in the recent period
ATCC 25285 is also one of pathogenic bacteria therein.
The content of the invention
It is an object of the invention to provide a kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp.
In order to realize the purpose of the present invention, the present invention provides a kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp, described
Pharmaceutical composition includes the compound and pharmaceutically acceptable carrier of effective dose, and the compound has having structure：
Preferably, the pharmaceutically acceptable carrier is diluent, disintegrant, adhesive, lubricant, stabilizer or rectified
Positive agent.
Preferably, the diluent is sugar derivatives, starch derivatives or cellulose derivative.
Preferably, the diluent is lactose.
Preferably, described pharmaceutical composition is powder, fine granule, granule, capsule or tablet.
The present invention also provides purposes of the compound in the external medicine for suppressing bacteroides fragilis ATCC 25285 is prepared, should
Compound has having structure：
Term " pharmaceutically acceptable " used herein refer to the biological activity that does not eliminate compound as described herein or
The material of property, such as carrier or diluent.This kind of material, which is applied to individual, does not cause undesirable biological action or not
Interacted with any component in harmful way and the composition comprising it.
Term " pharmaceutically acceptable carrier " as used herein includes any and all solvent, decentralized medium, bag
Clothing material, surfactant, antioxidant, preservative (such as antiseptic, antifungal agent), isotonic agent, absorption delaying agent, salt,
Preservative, drug stabilizing agent, adhesive, excipient, disintegrant, lubricant, sweetener, flavouring, dyestuff etc. and its combination, this
It is well-known to those skilled in the art (for example, see Remington's Pharmaceutical Sciences, 18th
Ed.Mack Printing Company,1990,pp.1289-1329).In addition to the carrier incompatible with active component, controlling
Consider to use any conventional carrier in treatment or pharmaceutical composition.
The compound of the present invention is for causing the pathogen effect of tooth body infections of dental pulp notable, and can develop into clinically has
The new pharmaceutical composition of effect.
Embodiment
Below by way of the description of embodiment, the invention will be further described, but this is not the limit to the present invention
System, those skilled in the art are according to the basic thought of the present invention, and various modifications may be made or improves, but without departing from this
The basic thought of invention, within the scope of the present invention.
Purposes of the experimental example the compounds of this invention in the external medicine for suppressing bacteroides fragilis ATCC 25285 is prepared
Research
Bacteriostatic test
Using following compounds, bacteriostatic test is carried out using filter paper enzyme classical in this area, wherein：
The structural formula of target compound is：
Shanghai Sang Ge bio tech ltd is purchased from for examination strain bacteroides fragilis ATCC 25285.
Nutrient solution
Nutrient agar and nutrient broth, purchased from Chen Yu experimental facilities Co., Ltd of BeiJing ZhongKe.
Test method
Bacteroides fragilis ATCC 25285 is inoculated on agar plate nutrition fluid level, uniformly gathered during inoculation.
0.01 gram of target compound is weighed, 15000 milliliters of sterilized waters of addition are ultrasonic 30 minutes, then 0.22 μm of micropore
Membrane filtration, obtains solution.The sterile circular filter paper piece of tweezer, sprays above-mentioned solution to complete wetting, is attached to inoculated bacteria
On agar plate nutrition fluid level.In the incubator that agar plate is placed in 37 DEG C, incubate 18 hours.Measure the straight of antibacterial ring size
Footpath.Determine 3 times and average.
1.4 results
The average diameter of bacteroides fragilis ATCC 25285 antibacterial ring size is 13.56mm, and this shows that target compound has
Extremely strong external suppression bacteroides fragilis ATCC 25285 effect.
Claims (2)
1. a kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp, it is characterised in that described pharmaceutical composition includes effective dose
Compound and pharmaceutically acceptable carrier, the compound have having structure：
2. the pharmaceutical composition of preventing and treating tooth body infections of dental pulp according to claim 1, it is characterised in that described pharmaceutically
The carrier of receiving is diluent, disintegrant, adhesive, lubricant, stabilizer or corrigent.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710108420.5A CN106924261A (en) | 2016-04-12 | 2016-04-12 | A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp |
| CN201610225691.4A CN105796564B (en) | 2016-04-12 | 2016-04-12 | A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610225691.4A CN105796564B (en) | 2016-04-12 | 2016-04-12 | A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710108420.5A Division CN106924261A (en) | 2016-04-12 | 2016-04-12 | A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105796564A CN105796564A (en) | 2016-07-27 |
| CN105796564B true CN105796564B (en) | 2017-07-11 |
Family
ID=56460001
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710108420.5A Pending CN106924261A (en) | 2016-04-12 | 2016-04-12 | A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp |
| CN201610225691.4A Expired - Fee Related CN105796564B (en) | 2016-04-12 | 2016-04-12 | A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710108420.5A Pending CN106924261A (en) | 2016-04-12 | 2016-04-12 | A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN106924261A (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7410974B2 (en) * | 2003-08-08 | 2008-08-12 | Ulysses Pharmaceutical Products, Inc. | Halogenated Quinazolinyl nitrofurans as antibacterial agents |
| WO2015019121A1 (en) * | 2013-08-09 | 2015-02-12 | Vichem Chemie Kutató Kft. | Styryl quinazoline derivatives as pharmaceutically active agents |
-
2016
- 2016-04-12 CN CN201710108420.5A patent/CN106924261A/en active Pending
- 2016-04-12 CN CN201610225691.4A patent/CN105796564B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN106924261A (en) | 2017-07-07 |
| CN105796564A (en) | 2016-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104667267A (en) | Lysozyme compound agent for skin external use and preparation method of lysozyme compound agent | |
| CN105796564B (en) | A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp | |
| CN104083364B (en) | A kind of pharmaceutical composition for the treatment of the infantile respiratory tract infection that enterobacter cloacae causes | |
| CN105997990B (en) | Purposes of the compound in the external medicine for suppressing C.perfringens ATCC 13124 is prepared | |
| CN105198903B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| CN105348270B (en) | A kind of pharmaceutical composition for preventing and treating tooth body infections of dental pulp | |
| RU2613708C2 (en) | Ways of acne treatment | |
| CN105191948B (en) | A kind of control laboratory disinfectant | |
| CN105395538B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| CN106806367A (en) | A kind of pharmaceutical composition for treating infections after burn | |
| CN105012201B (en) | The oral care product with anti-helicobacter pylori of the alcohol extract containing Chinese hawthorn seed | |
| CN105748477B (en) | A kind of medicine treating infantile enteritiss | |
| CN105232550B (en) | A kind of pharmaceutical composition treating chronic pelvic inflammatory disease | |
| CN102648904B (en) | Application of curcumin-zinc compound in preparing health-care nursing product | |
| CN107028958A (en) | Applications of the holarrhine B in antibacterial medicines activity is improved | |
| CN105348183A (en) | Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom | |
| CN105125546A (en) | Medicine composition for treating postoperative wound infection | |
| CN105232542B (en) | A kind of pharmaceutical composition for the treatment of infantile pneumonia | |
| CN105560234A (en) | Medicine composition for treating oral and maxillofacial inflammation | |
| CN105601475A (en) | Gingivitis treatment pharmaceutical composition | |
| CN105287478B (en) | A kind of pharmaceutical composition treating gastritis | |
| CN105622619A (en) | Medicine composition for treating periodontitis | |
| CN105232504B (en) | A kind of pharmaceutical composition for the treatment of infantile respiratory tract infection repeatedly | |
| CN105237542A (en) | Medicine composition for treating gynecological diseases | |
| CN105853434A (en) | Medicinal composition for treating gingivitis in orthodontic children |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Xinhong Inventor after: Zhang Jianan Inventor after: Li Mei Inventor after: Yang Jing Inventor before: Li Chun |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170613 Address after: Donghai Road 266000 Shandong city of Qingdao province No. 5 Applicant after: Qingdao Municipal Hospital Address before: 050043 No. 9, North Second Ring Road, Hebei, Shijiazhuang Applicant before: Li Chun |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170711 Termination date: 20180412 |